MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, today announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 with standard of care (SOC) vs placebo with SOC in patients with severe acute lung injury and critical illness.